business
Pathos AI raises $237 million for AI-driven drug development
Pathos AI raised $237 million in a Series E round led by Bristol Myers Squibb at a $3 billion valuation.
Key points
- Pathos AI uses its Foundry platform, which accesses 200 petabytes of oncological data, to identify promising cancer drug molecules.
- The company will pay Tempus AI Inc. $55 million over five years to license anonymized neurological patient data.
- Bristol Myers Squibb will gain access to the Foundry platform and Tempus dataset to improve clinical trials and patient identification.
Why it matters. The funding and partnerships may accelerate the development of biomarker-driven cancer therapies by integrating massive datasets with AI agents.
Pathos AI Inc. raised $237 million in a Series E round today at a $3 billion valuation. Bristol Myers Squibb Co. led the investment, which included participation from NEA, General Atlantic, and AstraZeneca plc. CEO Iker Huerga stated the funds will finance drug development, specifically the JSKN016 antibody-drug conjugate program and a joint ER PROTAC project with AstraZeneca.
Latest updates
Pathos AI raises $237 million for AI-driven drug development
Pathos AI Inc. announced the closure of a funding round totaling $237 million. The investment was led by Bristol Myers Squibb Co., signaling strong industry interest in AI-integrated drug discovery. The startup aims to use its platform to identify novel therapeutic targets more efficiently than traditional methods. The company's valuation has reached billion-dollar status following this capital injection.